ClinicalTrials.gg
CompletedNCT05430776Updated Nov 2, 2026

Laser Therapy on Tension-type Cephalea and Orofacial Pain in Post-covid-19 Patients

An interventional study of Photobimodulation in Tension-Type Headache, Orofacial Pain and COVID-19, sponsored by University of Nove de Julho. Completed at 2 sites in Brazil. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Nove de Julho · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Considering the auxiliary potential effect of photobiomodulation in controlling persistent CTT and TMD-related pain in patients who have been diagnosed with COVID-19, and are recovered from the viral infection, we intend to conduct a clinical trial comparing two modalities of therapeutic laser application: local application and transcutaneous application in the radial artery.

One of the main advantages of auxiliary techniques in pain control is the decrease of the use of drugs for analgesia, avoiding side effects and tolerance caused by them, and promoting an improvement in the individual's quality of life.

Read the detailed description

Orofacial pain and tensional cephalea were symptoms commonly reported in COVID-19 patients, even after recovery, and were considered chronic pain in these cases. The pain control, in these cases, is mostly accomplished with the use of analgesic and anti-inflammatory drugs. However, there are auxiliary treatments that can reduce the amount of pharmacological intake and improve the quality of life of compromised individuals, one of them is photobiomodulation. Using lasers for treatments to control inflammation and pain is successfully performed, but the parameters and the ways of application are not yet strongly established. The aim of this research is to evaluate the effect of the application of photobiomodulation with red and infrared lasers applied locally and systemically. For this purpose, individuals who have been diagnosed with COVID-19 and have had a tension headache and/or orofacial pain for more than 3 months will be selected by convenience. The participants will be divided into two different groups: G1- photobiomodulation with red and infrared laser with local application on the pain points (808 nm and 660 nm,100 mW, 6J per point) and G2 -photobiomodulation with red laser with transcutaneous application on the radial artery (660 nm, 100mW, 30 minutes). All participants will be treated for a period of 4 weeks, with 8 application sessions. The effects will be measured by means of blood lactate level, Brief Pain Inventory, Visual Analog Scale (VAS), and Cephalea Impact Test.

02

Conditions studied

  • Tension-Type Headache
  • Orofacial Pain
  • COVID-19

Keywords

  • tension-type headache
  • orofacial pain
  • photobiomodulation
  • covid-19
03

In context

Tension-Type Headache

144 studies on the registry are indexed under Tension-Type Headache; 42 are open to participants now.

This study's enrollment of 59 is close to the median of 60 across 109 interventional studies indexed under Tension-Type Headache.

Browse Tension-Type Headache studies →

Lead sponsor

University of Nove de Julho is the lead sponsor of 246 studies on the registry; 52 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals of both sexes, between the ages of 19 and 65, complaining of persistent orofacial pain or functional-type cephalea, for more than 3 months.
  • Individuals diagnosed with COVID-19, confirmed by RT-PCR for SARS-CoV-2 already recovered, at least 30 days after infection.

Exclusion criteria

Exclusion Criteria:

  • Individuals with diagnoses of neuropathies and headaches other than tension-type headache
  • Physical or intellectual incapacity to answer the survey questionnaires; illiterate; diabetics, pacemakers, and pregnant women.
  • Individuals who report photosensitivity to laser.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Active comparator
    Local photobiomodulation

    photobiomodulation with red and infrared laser with local application on pain points and

    Radiation: Photobimodulation

  • Experimental
    Systemic photobiomodulation

    photobiomodulation with red laser with transcutaneous application in the radial artery.

    Radiation: Photobimodulation

Interventions

  • RadiationPhotobimodulation

    laser therapy application

06

What researchers measure

Primary outcomes

  1. headache and orofacial pain

    headache and orofacial pain by analogic visual escale

    Time frame: four weeks

07

Study locations

2 sites
  • Nove de Julho Univ
    São Paulo, São Paulo 18133-399, Brazil
  • Lara Motta
    São Roque, São Paulo 18133-399, Brazil
08

References and documents

Publications

  • Costanti Vilela Campos M, Simoes Velloso Schuler S, de Barros Motta P, Catia Mazzoni A, Cristina da Silva F, Domingues Martins M, Porta Santos Fernandes K, Agnelli Mesquita-Ferrari R, Ratto Tempestini Horliana AC, Kalil Bussadori S, Jansiski Motta L. The effect of systemic versus local transcutaneous laser therapy on tension-type cephalea and orofacial pain in post-COVID-19 patients: A pragmatic randomized clinical trial. Medicine (Baltimore). 2022 Nov 18;101(46):e31218. doi: 10.1097/MD.0000000000031218. PubMed 36401476 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2023, 12 months.

Of 50 non-industry interventional studies with no phase under Tension-Type Headache, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 32. This study's 12 months is above that.

Counting every sponsor, half of 50 studies reached it within 9 months; a quarter within 3 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion May 2022 → May 2023 and completion Sep 2023 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2022
First posted
Jun 24, 2022
StartActual
May 10, 2022
Primary completionActual
May 10, 2023was May 2022
CompletionActual
Nov 29, 2024was Sep 2023
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 2, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Brazil)
  • Nove de Julho Univ · São Paulo, Brazil
  • Lara Motta · São Roque, Brazil
Show 2 removed
  • Lara Motta · Sao Roque, Brazil
  • Nove de Julho Univ · São Paulo, Brazil
Nov 2, 2026
Primary completion
May 10, 2022→May 10, 2023
Nov 2, 2026
Study completion
Sep 20, 2023→Nov 29, 2024 (actual)
Nov 2, 2026
Enrollment
40 (estimated)→59 (actual)
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Status unknown→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 Brazil)
    • Nove de Julho Univ · São Paulo, Brazil
    • Lara Motta · São Roque, Brazil
    Show 2 removed
    • Lara Motta · Sao Roque, Brazil
    • Nove de Julho Univ · São Paulo, Brazil
    Primary completion May 10, 2022→May 10, 2023
    Study completion Sep 20, 2023→Nov 29, 2024 (now actual)
    Enrollment 40 (estimated)→59 (actual)
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05430776
Responsible party
Lara Jansiski Motta (PhD, University of Nove de Julho) — Principal investigator
First posted
Jun 24, 2022
Start date
May 10, 2022
Primary completion
May 10, 2023
Completion
Nov 29, 2024
Last update
Nov 2, 2026

Study contacts

Lara Motta, Phd
principal investigator · Nove de Julho University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion